Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Interstitial Lung Disease
100%
Adjunct Therapy
100%
Intravenous Immunoglobulin (IVIg)
100%
Autoimmune Disease
40%
Immunosuppression
40%
Chemokines
20%
Immune Cells
20%
Systemic Lupus Erythematosus
20%
Pulmonary Disease
20%
Effector Function
20%
Connective Tissue Disease
20%
Antineutrophil Cytoplasmic Antibody-associated Vasculitis
20%
Immunomodulatory Effect
20%
Kawasaki Disease
20%
Pathogenic Autoantibodies
20%
Complement Activation
20%
Systemic Toxicity
20%
Inflammatory Disorders
20%
Refractory Cases
20%
Plasma Products
20%
Pooled Plasma
20%
Traditional Agents
20%
Inflammatory Myopathy
20%
Medicine and Dentistry
Adjuvant Therapy
100%
Interstitial Lung Disease
100%
Immunoglobulin
100%
Immunosuppressive Treatment
28%
Cytokine
14%
Morbidity
14%
Myopathy
14%
Autoimmune Disease
14%
Systemic Lupus Erythematosus
14%
Effector Cell
14%
Inflammatory Disorder
14%
Silo-Filler's Disease
14%
Immunocompetent Cell
14%
Chemokine
14%
ANCA Associated Vasculitis
14%
Autoantibodies
14%
Connective Tissue Disease
14%
Kawasaki Disease
14%
Neutralization
14%
Autoimmunity
14%
Complement Activation
14%
Treatment of Interstitial Lung Disease
14%
Immunology and Microbiology
Intravenous Immunoglobulin
100%
Lung
100%
Immunosuppression
28%
Immunocompetent Cell
14%
Chemokine
14%
Autoimmunity
14%
Cytokine
14%
Neutralization
14%
Autoimmune Disease
14%
Effector Cell
14%
Autoantibodies
14%
Blood Plasma
14%
Systemic Lupus Erythematosus
14%
Inflammatory Disorder
14%
ANCA Associated Vasculitis
14%
Complement Activation
14%
Connective Tissue
14%
Morbidity
14%
Kawasaki Disease
14%
Pharmacology, Toxicology and Pharmaceutical Science
Immunoglobulin
100%
Interstitial Lung Disease
100%
Chemokine
14%
Cytokine
14%
Autoimmune Disease
14%
Autoantibodies
14%
Systemic Lupus Erythematosus
14%
Lung Disease
14%
Morbidity
14%
ANCA Associated Vasculitis
14%
Connective Tissue Disease
14%
Mucocutaneous Lymph Node Syndrome
14%
Myopathy
14%